Outcomes of adult patients with B-cell acute lymphoblastic leukemia with or without blinatumomab as bridging therapy prior to allogeneic hematopoietic stem cell transplantation.

IF 6.3 2区医学 Q1 ONCOLOGY

Chinese Journal of Cancer Research Pub Date : 2025-08-30 DOI:10.21147/j.issn.1000-9604.2025.04.08

Jiayu Huang, Yi Xia, Yuhang Cheng, Bingyang Shi, Yilei Ma, Ze Tian, Luxiang Wang, Chuanhe Jiang, Haiyang Lu, Weijie Cao, Yang Cao, Xiaodong Mo, Xiaoxia Hu

引用次数: 0

查看原文本刊更多论文

成年b细胞急性淋巴细胞白血病患者在异基因造血干细胞移植前接受或不接受blinatumomab作为桥接治疗的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Journal of Cancer Research 医学-肿瘤学

自引率

9.80%

发文量

1726

审稿时长

4.5 months

期刊介绍： Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.